Suppr超能文献

促肾上腺皮质激素释放因子及促肾上腺皮质激素释放因子2受体在大鼠缺血/再灌注诱导性肠炎发病机制中的作用

Involvement of corticotropin-releasing factor and corticotropin-releasing factor 2 receptors in pathogenesis of ischemia/reperfusion-induced enteritis in rats.

作者信息

Takeuchi K, Kumano A, Abe N, Kotani T

机构信息

Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan.

General Incorporated Association, Kyoto Research Center for Gastrointestinal Diseases, Karasuma-Oike, Kyoto, Japan.

出版信息

J Physiol Pharmacol. 2016 Oct;67(5):697-707.

Abstract

We herein investigated, using a corticotropin-releasing factor (CRF) agonist and antagonists, whether CRF plays a role in the pathogenesis of ischemia/reperfusion-induced small intestinal lesions in rats. Under pentobarbital anesthesia, the superior mesenteric artery was clamped (ischemia) for 75 min, followed by reperfusion with removal of the clamp. After a 24-h reperfusion, the area of hemorrhagic lesions that developed in the small intestine was measured. Urocortin I (CRF receptor 1/2 agonist), astressin (CRF receptor 1/2 antagonist), NBI27914 (CRF receptor 1 antagonist), or astressin 2B (CRF receptor 2 antagonist) was administered i.v. twice: 5 min before ischemia and 6 hours after reperfusion. Ischemia/reperfusion caused hemorrhagic lesions in the small intestine in ampicillin- and aminoguanidine-inhibitable manners, accompanied by enterobacterial invasion and the up-regulation of inducible nitric oxide synthase expression and myeloperoxidase activity. The severity of ischemia/reperfusion-induced lesions was significantly reduced by astressin and astressin 2B, but not by NBI27914, with the suppression of bacterial invasion, myeloperoxidase activity, and inducible nitric oxide synthase expression. In contrast, urocortin I markedly aggravated these lesions, and this response was completely abrogated by the co-administration of astressin 2B, but not NBI27914. The gene expression of CRF, CRF receptor 1, and CRF receptor 2 was observed in the small intestine, and remained unchanged following ischemia/reperfusion. These results suggest that ischemia/reperfusion caused hemorrhagic lesions in the small intestine, the pathogenesis of which involved enterobacteria and inducible nitric oxide synthase/nitric oxide. These lesions were aggravated by urocortin I in an astressin 2B-inhibitable manner, but suppressed by astressin in a CRF receptor 2-dependent manner. Endogenous CRF may be involved in the pathogenesis of ischemia/reperfusion-induced enteritis, possibly via the activation of peripheral CRF receptor 2.

摘要

我们在此使用促肾上腺皮质激素释放因子(CRF)激动剂和拮抗剂,研究CRF是否在大鼠缺血/再灌注诱导的小肠损伤发病机制中起作用。在戊巴比妥麻醉下,夹闭肠系膜上动脉(缺血)75分钟,然后移除夹子进行再灌注。再灌注24小时后,测量小肠中出现的出血性损伤面积。静脉注射尿皮质素I(CRF受体1/2激动剂)、阿斯特辛(CRF受体1/2拮抗剂)、NBI27914(CRF受体1拮抗剂)或阿斯特辛2B(CRF受体2拮抗剂)两次:缺血前5分钟和再灌注后6小时。缺血/再灌注以氨苄青霉素和氨基胍可抑制的方式在小肠中引起出血性损伤,伴有肠道细菌入侵以及诱导型一氧化氮合酶表达上调和髓过氧化物酶活性增加。阿斯特辛和阿斯特辛2B可显著减轻缺血/再灌注诱导的损伤严重程度,但NBI27914无此作用,同时可抑制细菌入侵、髓过氧化物酶活性和诱导型一氧化氮合酶表达。相反,尿皮质素I显著加重这些损伤,而阿斯特辛2B共同给药可完全消除这种反应,但NBI27914则不能。在小肠中观察到CRF、CRF受体1和CRF受体2的基因表达,缺血/再灌注后其保持不变。这些结果表明,缺血/再灌注在小肠中引起出血性损伤,其发病机制涉及肠道细菌和诱导型一氧化氮合酶/一氧化氮。这些损伤以阿斯特辛2B可抑制的方式被尿皮质素I加重,但以CRF受体2依赖性方式被阿斯特辛抑制。内源性CRF可能通过激活外周CRF受体2参与缺血/再灌注诱导的肠炎发病机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验